Cipla Limited

Sector: Pharmaceuticals  |  HQ: Mumbai, Maharashtra  |  Founded: 1935  |  Employees: ~25,000

Listed as: NSE / BSE listed; Nifty 50 constituent  |  NSE / BSE  |  Ticker: CIPLA.NS  |  Website →

Key people

• Y K Hamied (Non-Executive Chairman)
• Umang Vohra (CEO and MD)

Company overview

Cipla Limited is one of India's top-3 pharmaceutical companies by revenue, with a 90-year heritage going back to 1935. Headquartered in Mumbai with operations across India, USA, South Africa, Europe, and Emerging Markets, Cipla operates 47 manufacturing facilities globally. FY25 revenue was approximately ₹27,500 crore. The company is known for inhaled respiratory medicines, antiretrovirals (ARV) for HIV/AIDS treatment, and a deep generic and complex-generic pipeline.

Business model

Cipla operates four reporting segments: One India (domestic formulations), North America (US generics and specialty), South Africa, and Emerging Markets and Europe. The Indian business contributes the largest share of EBITDA. The US business is in growth phase with complex generics and inhalation launches.

Operating segments

Recent developments

May 2026

Cipla reported exceptional FY26 performance, achieving its highest-ever annual revenue of Rs. 28,163 crore, driven primarily by strong growth in its India business [2][3][4]. This represents a significant milestone and underscores the company's ability to expand its domestic market presence and deliver growth ahead of prior periods.

In governance and leadership, Cipla's board approved key managerial changes effective April 2026, with Achin Gupta set to assume the role of Managing Director and Global CEO, subject to shareholder approval [5][6]. Separately, Cipla entered a strategic partnership with Pfizer for the exclusive marketing and distribution of select brands in India, covering at least four brands, representing a meaningful collaboration with a global pharmaceutical leader [7][9][10].

Sources (8)

1. Cipla Reports Strong FY26 Growth Led by India Business - Machine Maker · Machine Maker · Thu, 14 May 2026
2. Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26 - Indian Pharma Post · Indian Pharma Post · Fri, 15 May 2026
3. Cipla Ltd stock (INE059A01026): Full Year 2026 Earnings Highlight India Growth - AD HOC NEWS · AD HOC NEWS · Thu, 14 May 2026
4. Cipla Seeks Shareholder Nod to Appoint Achin Gupta as MD, Global CEO - Medical Dialogues · Medical Dialogues · Tue, 24 Feb 2026
5. Cipla Limited Board Approves Key Managerial Personnel Changes Effective April 2026 - scanx.trade · scanx.trade · Fri, 23 Jan 2026
6. Pfizer & Cipla announce exclusive marketing and distribution partnership for select brands in India - BioSpectrum India · BioSpectrum India · Fri, 19 Dec 2025
7. Cipla, Pfizer ink partnership for exclusive marketing of four brands in India - The Economic Times · The Economic Times · Fri, 19 Dec 2025
8. Pfizer and Cipla announce partnership - The Hindu · The Hindu · Sat, 20 Dec 2025

Financial performance and recent trajectory

Cipla reported FY25 revenue of ₹27,500 crore with EBITDA margin in the 25-27 percent range. R&D spend is approximately 6-7 percent of revenue.

Stock performance and shareholder context

Cipla (NSE: CIPLA, BSE: 500087) is a Nifty 50 constituent. Hamied family holds approximately 33 percent.

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

Top-3 Indian pharma by revenue. Leader in respiratory (inhalers) and HIV/AIDS ARV. Top-10 global respiratory player.

Key risks

US FDA inspection findings; US complex-generic competition; INR-USD volatility; India price regulation.

Outlook

Strong outlook on respiratory and complex-generic launches through FY28.

KAMRIT point of view

Building or competing with Cipla?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Cipla and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 3 related project reports → Book a scoping call

Related KAMRIT project reports

These reports use Cipla Limited in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.